Abstract:Although classically recognized as a neurotransmitter, gamma aminobutyric acid (GABA) has also been identified in colonic tumors. Moreover, the gut microbiome represents another potential source of GABA. Both GABAA and GABAB receptors have been implicated in contributing to the effects of GABA in colorectal cancer, with both pro‐ and anti‐tumorigenic functions identified. However, their subunit composition is often overlooked. Studies to date have not addressed whether the GABA‐producing potential of the microbiome changes over the course of colon tumor development or whether receptor subunit expression patterns are altered in colon cancer. Therefore, we investigated the clusters of orthologous group frequencies of glutamate decarboxylase (GAD) in feces from two murine models of colon cancer and found that the frequency of microbial GAD was significantly decreased early in the tumorigenic process. We also determined that microbial‐derived GABA inhibited proliferation of colon cancer cells in vitro and that this effect of GABA on SW480 cells involved both GABAA and GABAB receptors. GABA also inhibited prostaglandin E2 (PGE2)‐induced proliferation and interleukin‐6 (IL‐6) expression in these cells. Gene expression correlations were assessed using the "Cancer Exploration" suite of the TIMER2.0 web tool and identified that GABA receptor subunits were differentially expressed in human colon cancer. Moreover, GABAA receptor subunits were predominantly positively associated with PGE2 synthase, cyclooxygenase‐2 and IL‐6. Collectively, these data demonstrate decreased potential of the microbiome to produce GABA during tumorigenesis, a novel anti‐tumorigenic pathway for GABA, and that GABA receptor subunit expression adds a further layer of complexity to GABAergic signaling in colon cancer.

GABAergic signaling beyond synapses: an emerging target for cancer therapy

GABAergic signaling as a potential therapeutic target in cancers

Insights into the leveraging of GABAergic signaling in cancer therapy

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Gaba(B) Receptor Complex As A Potential Target For Tumor Therapy

Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression

Tumor-derived GABA promotes lung cancer progression by influencing TAMs polarization and neovascularization

GABA regulates the proliferation and apoptosis of head and neck squamous cell carcinoma cells by promoting the expression of CCND2 and BCL2L1

The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma

Interplay between microbial‐derived GABA and host GABA receptor signaling collectively influence the tumorigenic function of GABA in colon cancer

Gamma-aminobutyric acid-mediated neuro-immune interactions in glioblastoma: Implications for prognosis and immunotherapy response

Γ-Aminobutyric Acid Inhibits the Proliferation and Increases Oxaliplatin Sensitivity in Human Colon Cancer Cells

Recent Advances in the Role of Toll-Like Receptors and Tlr Agonists in Immunotherapy for Human Glioma

Suppression of Human Liver Cancer Cell Migration and Invasion Via the GABAA Receptor

Targeting Innate Immunity in Glioma Therapy

Cancer Stem Cells in Glioblastoma—molecular Signaling and Therapeutic Targeting

Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy

G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression

Deciphering the CNS-glioma dialogue: Advanced insights into CNS-glioma communication pathways and their therapeutic potential

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Immunotherapy for Malignant Glioma: Current Status and Future Directions